Honasa buys 58% of Fluence Pharma for Rs 135 Cr, launches Honasa Health for nutraceuticals push
Mamaearth parent acquires majority stake in dermatologist-led nutraceuticals firm Fluence Pharma at Rs 135 crore EV, with remaining 42% to be picked up over 5-7 years. New subsidiary Honasa Health will tap the Rs 16,000 crore inside-out beauty market via D2C, leveraging a 3,000-dermatologist network.
What happened
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at Rs 135 crore EV, with remaining 42% over 5-7 years. Forms Honasa Health subsidiary to
Key facts
- 58% stake
- Rs 135 crore EV
- 42% remaining stake
- 5-7 years
- 3,000 dermatologists
- Rs 16,000 crore market
- Rs 40 crore FY26 revenue
- 20%+ EBITDA margin
- 70% revenue from hair
Why this matters
The staggered 58% now / 42% over 5-7 years structure is a template for de-risking founder-led healthtech buys—earnout-style alignment without diluting clinical credibility upfront.